Background: To study the genetic profile of infants with neonatal diabetes (NDM) and response to empirical glibenclamide.
Method: A retrospective study between 2014-2018, the data retreived from patients admitted with neonatal diabetes with genetic analysis. Started on insulin and empirical glibenclamide given in selected cases to evaluate the effects. Glibenclamide was started in 4 children who were not euglycemic on insulin, and had no syndromic features, non consanguineous parents.
Results: 11 children were diagnosed with NDM and genetic testing were done in all. 2 cases were KCJN11, one was HNF1B, one INS, one FOXP3, one EIF2AK3. 4 cases were started on oral glibenclamide and 3 responded well. No adverse events were noted in any of the infants.
Conclusion: glibenclamide is a safe drug for treating neonatal diabetes, and may be empirically tried in selected cases while awaiting the genetic results.
19 - 21 Sep 2019
European Society for Paediatric Endocrinology